BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24141626)

  • 1. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.
    Marri PR; Hodge LS; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Cerhan JR; Novak AJ; Ansell SM
    Clin Cancer Res; 2013 Dec; 19(24):6812-9. PubMed ID: 24141626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
    Tefferi A; Vaidya R; Caramazza D; Finke C; Lasho T; Pardanani A
    J Clin Oncol; 2011 Apr; 29(10):1356-63. PubMed ID: 21300928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
    Karube K; Niino D; Kimura Y; Ohshima K
    Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
    Hsi ED; Li H; Nixon AB; Schöder H; Bartlett NL; LeBlanc M; Smith S; Kahl BS; Leonard JP; Evens AM; Scott DW; Rimsza LM; Friedberg JW
    Blood; 2019 Apr; 133(16):1762-1765. PubMed ID: 30723079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis.
    Rutkowski P; Kaminska J; Kowalska M; Ruka W; Steffen J
    Int J Cancer; 2002 Aug; 100(4):463-71. PubMed ID: 12115531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.
    Gupta M; Stenson M; O'Byrne M; Maurer MJ; Habermann T; Cerhan JR; Weiner GW; Witzig TE
    Ann Oncol; 2016 Jan; 27(1):165-72. PubMed ID: 26487586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
    Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Measurement of five cytokines in the serum of malignant lymphoma patients].
    Zhu H; Wang Y; Han X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma.
    Paradisi R; Vicenti R; Macciocca M; Seracchioli R; Rossi S; Fabbri R
    Fertil Steril; 2016 Oct; 106(5):1176-1182. PubMed ID: 27430206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era.
    Wang Q; Qin Y; Zhou S; He X; Yang J; Kang S; Liu P; Yang S; Zhang C; Gui L; Sun Y; Shi Y
    Oncotarget; 2016 Nov; 7(44):72219-72228. PubMed ID: 27750215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
    Dlouhy I; Filella X; Rovira J; Magnano L; Rivas-Delgado A; Baumann T; Martínez-Trillos A; Balagué O; Martínez A; González-Farre B; Karube K; Gine E; Delgado J; Campo E; López-Guillermo A
    Leuk Res; 2017 Aug; 59():20-25. PubMed ID: 28544905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.
    Ansell SM; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Witzig TE; Macon WR; Dogan A; Cerhan JR; Novak AJ
    Am J Hematol; 2012 Sep; 87(9):865-9. PubMed ID: 22674570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
    Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
    Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma.
    Zanotti R; Trolese A; Ambrosetti A; Nadali G; Visco C; Ricetti MM; Benedetti F; Pizzolo G
    Ann Oncol; 2002 Dec; 13(12):1908-14. PubMed ID: 12453859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
    J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic serum cytokines in classical Hodgkin lymphoma--letter.
    Coutelle O; Büning H; Plütschow A; Fuchs M; Escalona-Espinosa L; Engert A; Hacker U
    Clin Cancer Res; 2014 Dec; 20(24):6633. PubMed ID: 25512637
    [No Abstract]   [Full Text] [Related]  

  • 18. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
    Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
    Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control Subjects.
    da Silva PB; Perini GF; Pereira Lde A; Sacconato EM; Penna AM; Garibaldi J; Cavalcante E; Baiocchi OC
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S151-7. PubMed ID: 26297269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.